niacinamide has been researched along with Friedreich Disease in 6 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nicotinamide was generally well tolerated; the main adverse event was nausea, which in most cases was mild, dose-related, and resolved spontaneously or after dose reduction, use of antinausea drugs, or both." | 1.40 | Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. ( Athanasopoulos, S; Chan, PK; Festenstein, R; Giunti, P; Huson, L; Law, PP; Leiper, J; Libri, V; Loyse, N; Mauri, M; Mohammad, T; Natisvili, T; Parkinson, MH; Piper, S; Ramesh, A; Tam, KT; Yandim, C, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Georges, P | 1 |
| Boza-Moran, MG | 1 |
| Gide, J | 1 |
| Pêche, GA | 1 |
| Forêt, B | 1 |
| Bayot, A | 1 |
| Rustin, P | 1 |
| Peschanski, M | 1 |
| Martinat, C | 1 |
| Aubry, L | 1 |
| Chan, PK | 2 |
| Torres, R | 1 |
| Yandim, C | 2 |
| Law, PP | 2 |
| Khadayate, S | 1 |
| Mauri, M | 2 |
| Grosan, C | 1 |
| Chapman-Rothe, N | 1 |
| Giunti, P | 2 |
| Pook, M | 1 |
| Festenstein, R | 2 |
| Libri, V | 1 |
| Athanasopoulos, S | 1 |
| Loyse, N | 1 |
| Natisvili, T | 1 |
| Mohammad, T | 1 |
| Tam, KT | 1 |
| Leiper, J | 1 |
| Piper, S | 1 |
| Ramesh, A | 1 |
| Parkinson, MH | 1 |
| Huson, L | 1 |
| Lynch, DR | 1 |
| Fischbeck, KH | 1 |
| DEMEULEMEESTER, F | 1 |
| DELAEY, P | 1 |
| HOOFT, C | 1 |
| TIMMERMANS, J | 1 |
| SNOECK, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacodynamic Studies of a Histone Deacetylase Inhibitor in Friedreich's Ataxia[NCT01589809] | Phase 2 | 40 participants (Anticipated) | Interventional | 2012-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for niacinamide and Friedreich Disease
| Article | Year |
|---|---|
Induced pluripotent stem cells-derived neurons from patients with Friedreich ataxia exhibit differential sensitivity to resveratrol and nicotinamide.
Topics: Apoptosis; Cell Survival; Cells, Cultured; Drug Design; Fibroblasts; Frataxin; Friedreich Ataxia; Ge | 2019 |
Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3.
Topics: Acetylation; Animals; Cell Line, Transformed; Chromatin; Deoxyribonuclease I; Epistasis, Genetic; Fr | 2013 |
Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.
Topics: Adult; Chromatin; Dose-Response Relationship, Drug; Epigenesis, Genetic; Female; Frataxin; Friedreic | 2014 |
Nicotinamide in Friedreich's ataxia: useful or not?
Topics: Female; Frataxin; Friedreich Ataxia; Humans; Iron-Binding Proteins; Male; Niacinamide; Vitamin B Com | 2014 |
[THE CLINICAL FORM OF HARTNUP'S DISEASE].
Topics: Diagnosis, Differential; Friedreich Ataxia; Hartnup Disease; Humans; Indican; Indoles; Infant; Metab | 1963 |
BIOCHEMICAL ASPECTS OF THE HARTNUP DISEASE. I. RESULTS OF INTRAVENOUS AND ORAL TRYPTOPHAN LOADING TESTS IN A CASE OF HARTNUP DISEASE.
Topics: Amino Acid Metabolism, Inborn Errors; Biomedical Research; Friedreich Ataxia; Genetics, Medical; Har | 1964 |